Epidemiologija raka jajnika u Hrvatskoj by Mario Šekerija & Petra Čukelj
3
REVIEW Libri Oncol., Vol. 43 (2015), No 1-3, 3 – 8
EPIDEMIOLOGY OF OVARIAN CANCER IN CROATIA
MARIO ŠEKERIJA and PETRA ČUKELJ
Croatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia
Summary
Ovarian cancer is one of the most lethal malignant cancers in women, mainly because of the late stage at diagnosis. It 
is the seventh most common cancer in women in the world in incidence (239,000,3.6%) andeighth in mortality (152,000, 
4.3%). More developed regions have higher incidence and mortality rates than developing countries. 
In Croatia, ovarian cancer ranks as the sixth most common cancer in women (430 new cases in 2013) and the sixth 
malignant cause of death (328 deaths in 2013). Research based on the Croatian National Cancer Registry data also shows that 
trends of standardized incidence and mortality rates for ovarian cancer in Croatia are relatively stable for the period from 
1988 to 2008, while recent studies oncancer survival (EUROCARE-5, CONCORD-2) rank Croatia close to the European 
mean when it comes to ovarian cancer survival. 
Ovarian cancer is asignifi cant public health burden in Croatia.  Eff orts should be put in education about symptoms, 
and some modifi able risk factors such as tobacco use, obesity and hormone replacement therapy.
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EPIDEMIOLOGIJA RAKA JAJNIKA U HRVATSKOJ
Sažetak
Rak jajnika jedna je od najsmrtonosnijih malignih bolesti u žena, uglavnom zbog kasnog dijagnosticiranja. To je sedmi 
najčešći rak po pojavnosti u žena u svijetu (239.000, 3,6%), a osmi po smrtnosti (152.000, 4,3%). Razvijenije regije imaju više 
stope učestalosti i smrtnosti od zemalja u razvoju.
U Hrvatskoj, rak jajnika je 2013. godine bio šesti najčešći rak u žena (430 novih slučajeva), te šesti maligni uzrok smrti 
(328 smrtnih slučajeva u 2013. godini). Istraživanjatemeljena na podacima Registra za rak Republike Hrvatske također 
 pokazuju da trendovi standardiziranih stopa incidencije i mortaliteta za rak jajnika u Hrvatskoj su relativno stabilni u raz-
doblju od 1988. do 2008. godine, a nedavna istraživanja koja su pratila preživljenje od raka (EUROCARE-5, CONCORD-2) 
rangiraju Hrvatska blizu europskog prosjeka po pitanju preživljenjaod raka jajnika.
Rak jajnika predstavlja značajan javnozdravstveni teret u Hrvatskoj. Napore treba usmjeriti u edukaciju o simptomi-
ma i nekim promjenjivim čimbenicima rizika, kao što su uporaba duhana, pretilost i hormonska nadomjesna terapija.
KLJUČNE RIJEČI: rak jajnika, Hrvatska, registri
Ovarian cancer is one of the most lethal ma-
lignant cancers in women today. Most common 
malignant type of ovarian cancer is epithelial car-
cinoma, which can, based on the histology, be fur-
ther divided in fi ve diff erent types: high-grade 
serous, clear cell, endometrioid, mucinous and 
low-grade serous carcinoma. These types are in 
fact distinct diseases, as they diff er in risk factors, 
patt erns of spread, response to treatment and 
prognosis. The most prevalent type is the high-
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Figure 2 Estimates of age-standardised (W) mortality rates of ovarian cancer in 2012 (4)
Figure 1 Estimates of age-standardised (World Standard Population - W) incidence rates of ovarian 
cancer in 2012 (4)
grade serous type, which also has the worst prog-
nosis (1).
Women with germline mutations in BRCA1 
or BRCA2 genes have a higher risk of developing 
breast and ovarian cancer; the estimated cumula-
tive risk for the latt er is 36%-63% in BRCA1 muta-
tion carriers, and 10%-27% in BRCA2 mutation 
carriers, compared with less than 2% in the gen-
eral population(2).
Early stages of cancer are asymptomatic, and 
in later stages symptoms can be mistaken for oth-
er common maladies as they include bloated 
stomach, discomfort in the pelvis area, change in 
bowel habits, and frequent need to urinate. Be-
cause of these non-specifi c symptoms ovarian 
cancer is usually diagnosed at later stages, when 
prognosis is poor. Also, very litt le is known about 
the aetiology of the disease. 
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Table 1
RISK FACTORS AND PROTECTIVE FACTORS 
FOR OVARIAN CANCER, ACCORDING TO (3)
Risk factors Protective factors
Age Oral  contraceptive use
Family history Oophorectomy
Nulliparity Hysterectomy
Increased numbers of lifetime 
ovulatory cycles
Tubal Ligation
Hormone replacement therapy Lactation






Figure 3 Estimates of age-standardised (W) ovarian cancer incidence and mortality rates in European 
countries in 2012 (4)
Ovarian cancer occurs most often in nullipa-
rous women and other risk factors include early 
age at menarche, late menopause, and no use of 
oral contraceptives. It can be concluded that sup-
pressed ovulation is a protective factor, and hy-
potheses about the aetiology of the disease corre-
spond to this observation(1). Incessant ovulation 
theory considers that constant epithelial repair 
which happens after every ovulation cycle in-
creases the risk for spontaneous mutations of 
ovarian epithelial cells. Gonadotropin hypothesis 
posits that gonadotropin hormones, such as LH 
and FSH, stimulate the ovarian epithelium and 
therefore promote proliferation, thereby increas-
ing the risk of neoplastic changes in the epitheli-
um (3).
According to GLOBOCAN 2012 (4), around 
239,000 new cases of ovarian cancer occur in the 
world every year, and a third of that number af-
fects women under the age of 50. It is the seventh 
most common cancer diagnosed in women (3.6%), 
a nd the eighth most c ommon cancer caus e of 
death (152,000, 4.3%) in  women. Almost half of all 
cases occur in Asia (112,000, 47.6%), and almost a 
third in Europ e (66,000,  27.5%), where  the highest 
incidence and morta lity rates are found in Cen tral 
and East ern Europe. Migration from countries 
with low disease burden to those having high 
rates of ovarian cancer results in greater ovarian 
cancer risk (5), highlighting the importance of 
non-genetic factors.
In Europe, countries with highest age-stan-
dardised incidence rates include Latvia, Bulgaria 
and Poland while the highest estimated mortality 
rates in 2012 have been found in Latvia, Lithuania 
and Poland (4). While Croatia ranks 20th (out of 40 
countries included) by incidence rates, it is ranked 
6th in mortality, indicating possibilities for improve-
ment of care for women with ovarian cancer.
The most recent offi  cial data for Croatia (6)
show that ovarian cancer is the sixth most com-
mon cancer in women (430 new cases; crude inci-
dence rate 19.5/100,000), and also the sixth most 
common cancer cause of death (328 deaths, crude 
mortality rate 14.9/100,000). Distribution of stages 
at diagnosis from the Croatian National Cancer 
Registry bulletin for 2013(6) showed that 18% of 
ovarian cancer cases were diagnosed at a localised 
stage, 18% with regional spreading or regional 
metastases, 29% with distant metastases, and the 
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stage of the disease was unknown for 35% of the 
cases at the time of diagnosis.
When analysing age-specifi c incidence rates 
in Croatia, we can see that the highest rates are 
found in the oldest age-groups, with 83% of all 
ovarian cancers diagnosed in women aged 50 and 
more. 
Croatian data for 2013 show some regional 
diff erences in standardised incidence and mortal-
ity rates, incidence rate for ovarian cancer being 
higher in northern and central parts of the country 
(ranges from 28.5/100,000to 11.7/100,000) and low-
er in the coastal area (lowest in the Lika-Senj 
County with 9.4/100,000), with the exception of 
high incidence (23.8/100,000) in Dubrovnik-Neret-
va Countyand Zadar County (20.9/100,000).
Mortality data do not show such clear diff er-
ences, with standardised mortality rates ranging 
from 25.6/100,000 to 8.1/100,000, and the highest 
rates observed in the Bjelovar-Bilogora, Brod-
Posavina and Dubrovnik-Neretva Counties. 
Epidemiological research of ovarian cancer 
incidence and mortality trends in Croatia shows 
three distinct trends in the period from 1988 to 
Figure 4 Distribution of new cancer cases in Croatia, 2013(6)
Figure 5 Age-specifi c incidence rates of ovarian cancer in Croatia, 2013 (6)
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Figure 6 Age-standardised (estimates of Croatian population in 2013) ovarian cancer incidence and 
mortality rates in Croatian counties in 2013, according to data from (6)
Figure 7 Ovarian cancer 5-year relative survivals in countries participating in EUROCARE-5, adapt-
ed from (9)
2008(7). In the period from 1988 to 1997, the trend 
was stable (Estimated Annual Percent Change 
(EAPC) 0.4 (95% CI -1.2 to 1.9)), between 1997 and 
2000 there was a non-signifi cant increase in inci-
dence (EAPC 8.1 (95% CI -7.4 to 26.2)), and from 
2000 to 2008 there was a signifi cant decrease 
(EAPC -3.1 (95% CI -4.8 to -1.4)). However, when 
observing the whole period, the trend was stable 
(Average Annual Percent Change (AAPC) 0.1% 
(95% CI -2.2 to 2.4)). 
The ovarian cancer mortality trends de-
scribed in the same publication (7) indicate that, in 
the 1988-1992 period a statistically non-signifi cant 
decrease in mortality was observed (AAPC -4.1 
(95% CI -10.2 to 2.3)), whereas in the 1992-2008 pe-
riod a statistically signifi cant increase in ovarian 
cancer mortality was observed in Croatia (AAPC 
1.2 (95% CI 0.4 to 1.9)). 
Recently, two major studies on cancer sur-
vival have been published; EUROCARE-5 (8, 9) 
Libri Oncol., Vol. 43 (2015), No 1–3, 3 – 8
8
and CONCORD-2 (10). The EUROCARE-5 study 
on cancer survival in Europe has included, for the 
fi rst time in its history, data from Croatia. It 
showed that 5-year relative survival from ovarian 
cancer (for women diagnosed between2000 and 
2007 and followed-up until the end of 2008) was 
38.6%, placing Croatia somewhere in the middle 
of 25 European countries included in the study. 
Another study that focused on cancer surviv-
al is the CONCORD-2 study(10) which evaluated 
cancer survival at the global level. It included in-
formation from 67 countries, and a total of over 25 
million cancer patients were available for analysis. 
The most recent data for ovarian cancer in Croatia 
(5.885 eligible patients) showed that 5-year sur-
vival for patients diagnosed in the 2005-2009 pe-
riod was 36.8%.
In summary, Croatia is a country with an in-
termediate ovarian cancer incidence (compared to 
other European countries), but a relatively high, 
and worrisome, increasing mortality. Data from 
recent international survival studies have shown 
that the 5-year survival in Croatia was comparable 
to that in similar European countries. 
While many risk factors for ovarian cancer 
have been identifi ed (3), they do not account for 
all of the variability in incidence, nor do they ex-
plain large increases in the risk of disease – conse-
quently, a number of possible causes of ovarian 
cancer are yet to be identifi ed. Eff orts should be 
made to educate about early symptoms, and raise 
awareness of some modifi able risk factors like to-
bacco use, sedentary lifestyle, obesity and hor-
mone replacement therapy.
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